Alnylam Pharmaceuticals, Inc. vs Intel Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.47 (market cap $29.60B), while Intel Corp trades at $101.58 (market cap $492.85B). The key difference: Intel Corp is far larger — about 16.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Intel Corp pays a 2.24% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | INTC | |
|---|---|---|
Market Cap | $29.60B | $492.85B |
Sector | Health | Technology |
52-Week High | $491.22 | $140.94 |
52-Week Low | $205.48 | $21.81 |
Enterprise Value | $27.56B | $513.66B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Intel (INTC) trades at $100.51, up 3.07% today, with a bullish technical signal and recent earnings beats. Revenue grew 25% year-over-year in Q2 2026, driven by data center and AI segments, though net income margins remain negative. The company recently upsized a stock offering to $20 billion to fund AI and manufacturing investments, causing some investor concern over dilution but supporting long-term growth initiatives.
Outlook is mixed: strong revenue growth and analyst consensus price target of $116.67 suggest upside, but high valuation ratios, negative profitability, and execution risks in the capital-intensive foundry business pose challenges. Investor sentiment is cautiously optimistic amid the AI-driven turnaround narrative.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →